Cumberland Pharmaceuticals announces retirement of EVP Leo Pavliv

CUMBERLAND PHARMACEUTICALS INC

Leo Pavliv retired as EVP, Chief Development & Operations Officer effective May 31, 2022.
Pavliv entered into a consulting agreement to remain as Operations Advisor to the company.
His regulatory, product development and manufacturing duties have been assigned to other executives.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Leo Pavliv

Executive Vice President, Chief Development & Operations Officer

CPIX · CUMBERLAND PHARMACEUTICALS INC

Effective: 2022-05-31
Filed: June 3, 2022, 7:59 PM ET

On May 31, 2022, Cumberland Pharmaceuticals Inc. ("Cumberland" or the "Company") announced the retirement of Leo Pavliv, Cumberland’s Executive Vice President, Chief Development & Operations Officer.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Leo Pavliv retired as Executive Vice President, Chief Development & Operations Officer at CUMBERLAND PHARMACEUTICALS INC.

Action: retired
Role: Executive Vice President, Chief Development & Operations Officer

Exact text from the filing

On May 31, 2022, Cumberland Pharmaceuticals Inc. ("Cumberland" or the "Company") announced the retirement of Leo Pavliv, Cumberland’s Executive Vice President, Chief Development & Operations Officer.

View on SEC.gov

CUMBERLAND PHARMACEUTICALS INC filing history →

Source: SEC EDGAR

accession 0001628280-22-016201

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.